This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Molecular Diagnostics Market & Forecast (By Application, Technology, Countries, Companies & Clinical Trials) To 2017: Global Analysis

Figure 8 1: A Healthcare 'Value-Net'

List of Tables:

Table 3 1: Global Molecular Diagnostics – Company Wise Market Share (Percent), 2010 – 2012Table 3 2: Global Molecular Diagnostics – Forecast for Company Wise Market Share (Percent), 2013 – 2017

Table 8 1: Molecular Platforms for Companion Diagnostics

Table 9 1: Detecting Respiratory Viruses in Upper and Lower Respiratory Tract Samples – Clinical Trials, 2012Table 9 2: Crizotinib Efficacy in Non-Small Cell Lung Cancer Patients with Anaplastic Lymphoma Kinase Translocation – Clinical Trials, 2012Table 9 3: A Clinical Trial to Assess the Efficacy and Safety of the Conversion to Everolimus – Clinical Trials, 2012Table 9 4: Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler – Clinical Trials, 2012Table 9 5: A Two Arm, Multi-Centre Clinical Evaluation of the xTAG Respiratory Viral Panel v3 Test – Clinical Trials, 2013Table 9 6: Collecting and Storing Tissue Samples from Patients with Rare or Cutaneous Non-Hodgkin Lymphoma – Clinical Trials, 2012Table 9 7: Biopsies of Cancer Patients for Tumor Molecular Characterization – Clinical Trails, 2012Table 9 8: Daptomycin versus Vancomycin in the Treatment of Nosocomial or Healthcare-associated MRSA Bacteremia – Clinical Trials, 2013Table 9 9: Collection of Tissue Samples for Cancer Research – Clinical Trials, 2012Table 9 10: Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma – Clinical Trials, 2012Table 9 11: Total Therapy Study XVI for Newly Diagnosed Patients with Acute Lymphoblastic Leukemia – Clinical Trials, 2012Table 9 12: Tumor Genomic Profiling in Patients Evaluated for Targeted Cancer Therapy, 2013Table 9 13: Congenital Muscle Disease Study of Patient and Family Reported Medical Information – Clinical Trials, 2013Table 9 14: Molecular and Diagnostic Classification of Non-Small Cell Lung Cancer from Fine Needle Aspirates – Clinical Trials, 2013Table 9 15: Extending Molecular Responses with Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) Patients in Chronic Phase – Clinical Trials, 2012Table 9 16: CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib – Clinical Trial, 2013Table 9 17: Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile – Clinical Trials, 2013Table 9 18: Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients – Clinical Trials, 2012Table 9 19: Radotinib versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients – Clinical Trials, 2012Table 9 20: Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG) – Clinical Trials, 2012

7 of 8

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $95.18 0.00%
FB $117.43 0.00%
GOOG $692.36 0.00%
TSLA $232.32 0.00%
YHOO $36.01 0.00%


Chart of I:DJI
DOW 17,750.91 -140.25 -0.78%
S&P 500 2,063.37 -18.06 -0.87%
NASDAQ 4,763.2240 -54.37 -1.13%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs